Sanofi considering an India-specific strategy to expand presence
The drug firm has just launched India’s first locally manufactured re-usable insulin pen in the country.
Mumbai, October 11, 2012: The French drug maker, Sanofi is in the process of charting an India-specific strategy in order to increase its share in India’s Rs 65,000 crore drug market. The India unit of the drug company has recently launched India’s first locally manufactured re-usable insulin pen under the brand name AllStar.
At a price of Rs 650 per pen, it is cheaper than similar imported pens in its category. "The new launch underlines Sanofi’s focus on diabetes, emerging markets and regionalised approach to finding solutions," said Shailesh Ayyangar, Managing Director, Sanofi India. It may be noted here that India has highest number of type-2 diabetic patients, a major reason why the anti-diabetic market has grown exponentially in the past few years.
The company said that Sanofi is the fastest growing MNC in the Indian pharmaceutical market and it has a revenue base of Rs 300-400 crore from diabetes products alone. The company also has a plan its place to focus on nutraceuticals and animal health business.
The company is expected to launch Merial in India focusing on the animal health category in the domestic market.